Key points are not available for this paper at this time.
The lipoprotein abnormalities first associated with insulin resistance (IR) and compensatory hyperinsulinemia were high plasma triglyceride (TG) and low HDL-cholesterol (HDL-C) concentrations (1)(2). It is now known that the characteristic IR-associated dyslipidemia also includes a shift to smaller, denser LDL particles (pattern B), enhanced postprandial lipemia, and decreased concentration of the more buoyant HDL particle, HDL2 (3)(4)(5). Recently, the IR-associated lipoprotein abnormalities that increase risk of coronary heart disease (CHD) have continued to expand. In addition to high plasma TG and low HDL-C concentrations (6)(7), at least three classes of TG-rich lipoproteins are both atherogenic and associated with increased CHD risk, including intermediate density lipoprotein (IDL; a TG-rich remnant product derived from VLDL metabolism) (8)(9), VLDL3 (the dense VLDL subclass) (10)(11), and TG-rich chylomicron remnants (8)(12)(13). Despite awareness of the myriad IR-associated proatherogenic lipoprotein abnormalities (1)(2)(3)(4)(5)(14)(15)(16)(17), we are unaware of previous publications in which both IR and all relevant lipoproteins were quantified in the same cohort of individuals. This is likely partly attributable to the unavailability of analytical methods to measure multiple lipoprotein CHD risk factors in a clinically useful manner. However, the validated vertical auto profile-II (VAP-II) methodology (18) provides a means to comprehensively identify the IR-associated dyslipidemic profile, and we have used VAP-II to compare lipoprotein characteristics of nondiabetic individuals stratified into IR and insulin-sensitive (IS) groups. The Stanford University Human Subjects Committee approved this study, and healthy volunteers from the San Francisco Bay Area gave informed consent. Participants underwent medical interview, anthropometric measurements, and a physical examination. Exclusion criteria included fasting plasma glucose >7.0 mmol/L (126 mg/dL), total bilirubin >34 μmol/L (2.0 mg/dL), serum albumin 175 μmol/L (2.0 mg/dL), weight change >3.0 kg in 3 months, and active substance abuse. Results of a complete blood count, chemical screening battery, and electrocardiogram were normal in all participants. Each participant underwent the insulin-suppression test, as introduced previously and validated by our group (19). Bilateral antecubital intravenous catheters were used for (a) 180-min infusion of octreotide acetate (0.27 μg · m−2 · min−1), insulin (32 mIU · m−2 · min−1), and glucose (267 mg · m−2 · min−1); and (b) collection of timed blood samples every 30 min initially, and then every 10 min from 150 to 180 min of the infusion. These last four time points were used to determine the steady-state plasma glucose (SSPG) and insulin (SSPI) concentrations. Because SSPI concentrations are similar among individuals, the SSPG concentration directly measures the ability of insulin to mediate disposal of an infused glucose load; higher SSPG values indicate increasing IR. SSPG concentrations >10.8 mmol/L (195 mg/dL) were defined as IR, and SSPG 400 nondiabetic individuals that we tested previously (20). Using these criteria, we selected two groups: 23 IS and 21 IR individuals, none taking drugs known to affect blood pressure, glucose, or lipid metabolism. On a separate occasion, plasma glucose concentrations were determined before and 120 min after an oral 75-g glucose challenge. Plasma samples obtained after an overnight fast were stored frozen at −70 °C until lipoprotein analysis by the VAP-II method (18). VAP-II is a comprehensive lipoprotein profile testing method that directly measures cholesterol concentration in HDL2, HDL3, IDL, LDL, VLDL, and lipoprotein(a) Lp(a) in a single test. VAP-II has been extensively validated with the Lipid Research Clinics β-quantification method performed at Northwest Lipid Research Laboratories at the University of Washington, Seattle, WA (18)(21). It should be emphasized that this method provides a specific measure of narrow-density LDL-C (ND-LDL-C), in contrast to the commonly measured LDL-C defined by the National Cholesterol Education Program, which includes both Lp(a) and IDL-C. In VAP-II, the ND-LDL-C subclass pattern is further evaluated by determining the LDL peak maximum time, i.e., the relative position of the LDL peak in the density gradient on a relative scale of 0–200 s, with 0 s corresponding to the beginning of the HDL (the most dense lipoprotein) peak and 200 s corresponding to the VLDL (the least dense lipoprotein) peak maximum. Therefore, a patient with predominantly small, dense LDL has a lower LDL peak maximum time compared with the LDL peak maximum time of a patient with predominantly large, buoyant LDL. Thus, LDL pattern A (predominantly large and buoyant LDL subclass) is defined by a LDL maximum time >118 s, LDL pattern B by a LDL maximum time ≤115 s, and intermediate pattern (A/B) by LDL maximum time >115 and ≤118 s. Because the density and size of LDL are inversely related, we have compared VAP-II LDL peak maximum time (a function of density) with LDL size obtained by a commonly used 2–16% nondenaturing polyacrylamide gradient gel electrophoresis method performed at Pacific Biometrics Inc. (a CDC lipid-standardized laboratory), with a correlation coefficient of 0.832, and with the Nuclear Magnetic Resonance method performed at Liposcience Inc. (Raleigh, NC), with a correlation coefficient of 0.91 (unpublished data). VAP-II is based on use of a density gradient formed with 40-fold-diluted (40 μL of original serum) and density-adjusted (1.21 kg/L) serum and 1.006 kg/L density saline in a centrifuge tube. The gradient is subjected to a single vertical spin density-gradient ultracentrifugation at 416 000g for 36 min, using the Beckman Optima-XL 100K ultracentrifuge. The separated lipoprotein classes and subclasses are then continuously drained from the bottom of the centrifuge tube into the VAP-II continuous flow analyzer, where they react sequentially with a cholesterol-specific enzymatic reagent, producing a concentration-dependent lipoprotein absorbance profile monitored by a spectrophotometer. The digital output of the spectrophotometer is also acquired by a computer and is further deconvoluted with use of in-house-developed software to provide cholesterol concentrations of individual lipoprotein classes and subclasses. The VAP is provided by Atherotech, Inc., a CDC-National Heart, Lung, and Blood Institute-standardized lipid laboratory. Data are expressed as the mean (SE). The Student t-test and the χ2 test were used to make comparisons between experimental groups. All statistical evaluations were performed with the SYSTAT 10.0 software package for Windows. Statistical significance was assigned at P 0.60. By selection, SSPG concentrations were higher in the IR group 13.1 (0.3) vs 4.0 (0.1) mmol/L; P <0.01. Fasting and 120-min post-glucose load concentrations of glucose were also higher in the IR group 5.6 (0.1) vs 5.2 (0.1) and 7.2 (0.4) vs 4.9 (0.3) mmol/L; both P <0.01. The VAP lipoprotein analysis is given in Table 1 . The IR group had lower concentrations of both HDL subclasses, HDL2 (P <0.001) and HDL3 (P <0.001). Moreover, total TG concentrations were higher in the IR individuals (P <0.01), as were concentrations of all measured TG-rich lipoprotein classes, including IDL (P = 0.02); large, buoyant TG-rich VLDL1 + 2 (P <0.01); and the small, dense cholesterol-rich VLDL3a + 3b (P <0.001). Although LDL-C appeared to be higher in the IR individuals (3.44 vs 3.24 mmol/L; P = 0.39), this effect was partially attributable to the effects of a significantly higher IDL (0.49 vs 0.39 mmol/L; P = 0.02) in the setting of almost identical Lp(a) concentrations (0.19 vs 0.18 mmol/L; P = 0.85). Consequently, the directly measured ND-LDL-C concentrations were similar in the two groups (2.77 vs 2.67 mmol/L; P = 0.62). However, despite the similar concentrations of ND-LDL-C, the IR group had, on average, a small, denser LDL particle as indicated by a lower LDL maximum time (P <0.001), accompanied by a significantly higher proportion (P <0.001) of IR individuals identified with LDL pattern B (17 of 21) compared with IS individuals (4 of 23). Lipoprotein concentrations in 44 healthy nondiabetic volunteers as measured by the VAP-II methodology.1 All values are the mean (SE) in mmol/L unless otherwise noted. Lipoprotein concentrations in 44 healthy nondiabetic volunteers as measured by the VAP-II methodology.1 All values are the mean (SE) in mmol/L unless otherwise noted. The results of this study demonstrate that IR individuals have increased concentrations of TG and various TG-rich lipoprotein cholesterol, decreased concentrations of both HDL subclasses, and a pattern of small, dense LDL. All of these lipoprotein patterns predispose to an increased risk of CHD (6)(7)(8)(9)(10)(11)(12). Although these findings have previously been reported separately to associate with the metabolic syndrome, they are not all routinely measured in assessing the impact of IR on lipoprotein metabolism. The importance of IR and its consequences have recently been emphasized by the report of the Adult Treatment Panel III outlining diagnostic criteria for identifying IR/hyperinsulinemic individuals with the metabolic syndrome (22). Because ∼25% of the US population appears to have the metabolic syndrome as defined by the suggested criteria (23), it is of obvious importance to understand the relationship between the various components of IR and CHD. Although abnormal lipoprotein metabolism in the metabolic syndrome clearly contributes to CHD risk, the precise roles played by any particular member of the IR-associated atherogenic profile remain unclear (Table 1 ). The ability to quantify all such lipoprotein variables would help to further elucidate these complex relationships. In conclusion, our results demonstrate that multiple abnormalities in lipoprotein metabolism constitute the atherogenic lipoprotein profile present in nondiabetic IR individuals. The VAP-II method provides a relatively simple approach to identifying all such components in an individual. The application of VAP-II may be useful not only in elucidating the roles played by specific lipoprotein abnormalities in contributing to CHD, but also in yielding valuable insight into the specific benefits of therapeutic regimens to decrease CHD risk. This work was supported by National Institutes of Health Grants HL07708 (to J.W.C.) and M01-RR070.
Chu et al. (Sun,) studied this question.